Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

288
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
288
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

496
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
496
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.8K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

218
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
218
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

232
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
232
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

301
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
301

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Numerical and Experimental Analysis of Drug Inhalation in Realistic Human Upper Airway Model.

Pharmaceuticals (Basel, Switzerland)·2023
Same author

Numerical and Machine Learning Analysis of the Parameters Affecting the Regionally Delivered Nasal Dose of Nano- and Micro-Sized Aerosolized Drugs.

Pharmaceuticals (Basel, Switzerland)·2023
Same author

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin.

Pharmaceutics·2022

Related Experiment Video

Updated: Jan 6, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.8K

QSP-Copilot: An AI-Augmented Platform for Accelerating Quantitative Systems Pharmacology Model Development.

Anuraag Saini1, Ali Farnoud1

  • 1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

CPT: Pharmacometrics & Systems Pharmacology
|October 29, 2025
PubMed
Summary

QSP-Copilot, an AI tool, streamlines drug development by automating QSP modeling, reducing development time by 40% and enhancing transparency for rare diseases.

Keywords:
QSP‐copilotagentic workflowsartificial intelligence (AI)knowledge integrationlarge language models (LLMs)quantitative systems pharmacology (QSP)rare diseases

More Related Videos

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
05:47

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

14.5K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.3K

Related Experiment Videos

Last Updated: Jan 6, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.8K
In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
05:47

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

14.5K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.3K

Area of Science:

  • Pharmacology
  • Computational Biology
  • Artificial Intelligence

Background:

  • Quantitative Systems Pharmacology (QSP) aids drug development but faces challenges in knowledge integration, model construction, validation, and scalability.
  • Traditional QSP workflows are often slow, labor-intensive, and lack consistent validation, hindering efficient application.

Purpose of the Study:

  • To introduce QSP-Copilot, an AI-augmented solution to enhance QSP modeling workflows.
  • To address limitations in traditional QSP by automating tasks and improving scalability and transparency.

Main Methods:

  • Development of QSP-Copilot, an end-to-end AI solution using a multi-agent system and large language models (LLMs).
  • Modular support for QSP tasks including project scoping, model structuring, evaluation, and reporting.
  • Application and validation of QSP-Copilot on rare diseases: blood coagulation and Gaucher disease.

Main Results:

  • QSP-Copilot reduces QSP model development time by approximately 40% through task automation.
  • Achieved high extraction precision: 99.1% for blood coagulation and 100.0% for Gaucher disease.
  • Systematic documentation by QSP-Copilot improves methodological transparency and reduces manual curation burden.

Conclusions:

  • QSP-Copilot significantly improves efficiency and transparency in QSP modeling workflows.
  • AI-augmented workflows like QSP-Copilot are pivotal for enhancing scalability and impact in drug development, especially for rare diseases.
  • QSP-Copilot facilitates knowledge integration and model construction in biologically complex or data-sparse areas.